Your Partners for the
Next Generation of Metabolic Health
Committed to a smarter, more agile approach to biotech innovation – one company at a time.
Accelerating the Development of Transformative Patient Therapies
501 Ventures is a venture capital firm committed to a smarter and more agile approach to metabolic health innovation. We are focused on harnessing cutting-edge science to develop transformative therapies targeting metabolic health, preventing disease, and dramatically extending healthy life years globally.
Services
Our firm specializes in supporting life sciences companies at critical growth and transition points. Through a combination of strategic advisory services and investment support, 501 Ventures serves clients through critical milestones at every stage of company development.
ADVISORY SERVICES
We provide strategic and scientific advisory offerings to help companies navigate a complex partnering and M&A environment. In addition to selective M&A advisory work in the metabolic health sector, 501 Ventures conducts the majority of clinical work "in house," allowing for shared resources across the firm's portfolio companies.
INVESTMENT SUPPORT
We offer tailored investment vehicles and financial structuring to accelerate innovation in life sciences.
Targeted average placements ranging from $10 – $25M.
Investment Profile
Investment Size: Investments range from $10 – $25M each.
Focus: Focused on novel targets and novel science within Metabolic Health.
Target Stage: Assets that are two years to the clinic through Phase 2.
Investment Goal: 10 total Investments, taking a majority stake.
Lifecycle: The fund has a 10-year period, with a first five-year investment period.
Note: Up to 5% of the total core fund size will be allocated to Discovery investments.
Therapeutic Focus Areas
CARDIOMETABOLIC
Obesity
Diabetes
Cardiovascular Diseases
IMMUNOLOGY & INFLAMMATION
Autoimmune Diseases
Osteoarthritis
Meet the Founders
Enrique Conterno
MANAGING DIRECTOR
A seasoned senior executive with extensive experience in the Cardiometabolism field.
Enrique reestablished Eli Lilly’s industry position in diabetes and delivered unprecedented revenue growth by expanding into obesity and developing a best-in-class portfolio, including Jardiance, Trulicity, Mounjaro/Zepbound, and Orforglipron. He is currently a Board Member at Zealand Pharma and Glooko.
Currently a Board Member at: [ZEAL] [GLOOKO]
Meg Powell
MANAGING DIRECTOR
A proven Fortune 500 pharma executive operator turned serial entrepreneur and industry expert.
Meg's experience spans both large pharma and small startups—understanding the advantages and needs of both. Meg successfully created and exited two startups in the last decade, each returning ∼10x MOIC, including Target RWE, responsible for developing the largest curated global dataset in MASH. Meg is currently a Board Member at RTI International and Blue Cross and Blue Shield of North Carolina.
Currently a Board Member at: [RTI] [NC]